| Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial PM Voorhees, JL Kaufman, J Laubach, DW Sborov, B Reeves, ... Blood, The Journal of the American Society of Hematology 136 (8), 936-945, 2020 | 599 | 2020 |
| Oral selinexor–dexamethasone for triple-class refractory multiple myeloma A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, ... New England Journal of Medicine 381 (8), 727-738, 2019 | 593 | 2019 |
| Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated … CG Brunstein, EJ Fuchs, SL Carter, C Karanes, LJ Costa, J Wu, ... Blood, The Journal of the American Society of Hematology 118 (2), 282-288, 2011 | 576 | 2011 |
| Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy UH Gandhi, RF Cornell, A Lakshman, ZJ Gahvari, E McGehee, ... Leukemia 33 (9), 2266-2275, 2019 | 493 | 2019 |
| Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology JA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ... Journal of the National Comprehensive Cancer Network 17 (3), 255-289, 2019 | 489 | 2019 |
| Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations S Giralt, L Costa, J Schriber, J DiPersio, R Maziarz, J McCarty, ... Biology of Blood and Marrow Transplantation 20 (3), 295-308, 2014 | 435 | 2014 |
| NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020: featured updates to the NCCN guidelines JA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ... Journal of the National Comprehensive Cancer Network 18 (3), 230-241, 2020 | 354 | 2020 |
| Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States LJ Costa, IK Brill, J Omel, K Godby, SK Kumar, EE Brown Blood advances 1 (4), 282-287, 2017 | 278 | 2017 |
| Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma SM Smith, LJ Burns, K van Besien, J LeRademacher, W He, TS Fenske, ... Journal of clinical oncology 31 (25), 3100, 2013 | 261 | 2013 |
| Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow … HK Duong, BN Savani, E Copelan, S Devine, LJ Costa, JR Wingard, ... Biology of Blood and Marrow Transplantation 20 (9), 1262-1273, 2014 | 242 | 2014 |
| Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study A D'Souza, A Dispenzieri, B Wirk, MJ Zhang, J Huang, MA Gertz, RA Kyle, ... Journal of Clinical Oncology 33 (32), 3741-3749, 2015 | 206 | 2015 |
| Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma A Chari, MC Minnema, JG Berdeja, A Oriol, NWCJ van de Donk, ... New England Journal of Medicine 387 (24), 2232-2244, 2022 | 194 | 2022 |
| Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ... The Lancet Oncology 22 (3), e105-e118, 2021 | 192 | 2021 |
| Ide-cel or standard regimens in relapsed and refractory multiple myeloma P Rodriguez-Otero, S Ailawadhi, B Arnulf, K Patel, M Cavo, AK Nooka, ... New England Journal of Medicine 388 (11), 1002-1014, 2023 | 187 | 2023 |
| Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI EA Copelan, BK Hamilton, B Avalos, KW Ahn, BJ Bolwell, X Zhu, M Aljurf, ... Blood, The Journal of the American Society of Hematology 122 (24), 3863-3870, 2013 | 186 | 2013 |
| Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies LJ Costa, HA Drabkin The oncologist 12 (12), 1404-1415, 2007 | 186 | 2007 |
| Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing … TS Fenske, MJ Zhang, J Carreras, E Ayala, LJ Burns, A Cashen, LJ Costa, ... Journal of clinical oncology 32 (4), 273, 2014 | 166 | 2014 |
| Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma LJ Costa, S Chhabra, E Medvedova, BR Dholaria, TM Schmidt, KN Godby, ... Journal of Clinical Oncology 40 (25), 2901-2912, 2022 | 163 | 2022 |
| Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma DT Vogl, D Dingli, RF Cornell, CA Huff, S Jagannath, D Bhutani, J Zonder, ... Journal of clinical oncology 36 (9), 859, 2018 | 162 | 2018 |
| Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization LJ Costa, ET Alexander, KR Hogan, C Schaub, TV Fouts, RK Stuart Bone marrow transplantation 46 (1), 64-69, 2011 | 157 | 2011 |
Susan BalUniversity of Alabama at BirminghamDirección de correo verificada de uabmc.edu
